Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment-Reference-Cited by-同舟云学术

Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment

Published:2020-12 Issue: Volume:150 Page:90-96
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Subbiah Vivek,Paz-Ares Luis,Besse Benjamin,Moreno Victor,Peters Solange,Sala María Angeles,López-Vilariño José Antonio,Fernández Cristian,Kahatt Carmen,Alfaro Vicente,Siguero Mariano,Zeaiter Ali,Zaman Khalil,López Rafael,Ponce Santiago,Boni Valentina,Arrondeau Jennifer,Delord Jean-Pierre,Martínez Maite,Wannesson Luciano,Antón Antonio,Valdivia Javier,Awada Ahmad,Kristeleit Rebecca,Olmedo Maria Eugenia,Rubio María Jesús,Sarantopoulos John,Chawla Sant P.,Mosquera-Martinez Joaquín,D’ Arcangelo Manolo,Santoro Armando,Villalobos Victor M.,Sands Jacob,Trigo José

Funder

Pharma Mar S.A

Institute for Drug Development, Cancer Therapy and Research Center at University of Texas Health Science Center San Antonio, San Antonio, TX, USA

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference29 articles.

1. Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Fruh;Ann. Oncol.,2013

2. NCCN clinical practice guidelines in oncology;Small Cell Lung Cancer,2020

3. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung Cancer;Horn;N. Engl. J. Med.,2018

4. C. investigators, Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial;Paz-Ares;Lancet,2019

5. Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: a retrospective analysis;Korkmaz;Clin. Transl. Oncol.,2013

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of sintilimab in combination with chemotherapy for recurrent extensive-stage small cell lung cancer: a real-world retrospective study;Journal of Thoracic Disease;2024-06

2. Functionalized graphene oxide NPs as a nanocarrier for drug delivery system in quercetin/ lurbinectedin as dual sensitive therapeutics for A549 lung cancer treatment;Heliyon;2024-06

3. Lurbinectedin in small cell lung cancer: real‐world experience of a multicentre national early access programme;Internal Medicine Journal;2024-02-18

4. A pivotal bridging study of lurbinectedin as second-line therapy in Chinese patients with small cell lung cancer;Scientific Reports;2024-02-13

5. Lurbinectedin in patients with small cell lung cancer with chemotherapy-free interval ≥30 days and without central nervous metastases;Lung Cancer;2024-02